Cytokine Release Syndrome: Inpatient Care for Side Effects of CAR T-Cell Therapy .
Pediatric patients with relapsed and refractory acute lymphoblastic leukemia are more often being treated with chimeric antigen receptor (CAR) T-cell therapy. As with any new therapy, the management of this patient population has a unique set of challenges. The side effects of this therapy can range from mild to severe, with cytokine release syndrome being the most common reason for hospitalization. .



This article presents common side effects, treatments, and challenges of caring for hospitalized patients who have received CAR T-cell therapy. .



A case study is used to illustrate a patient's inpatient hospitalization course after receiving CAR T-cell therapy, including the management of treatment-related toxicities. .



As treatments emerge, nurses will be challenged with learning the associated side effects and toxicities. CAR T-cell therapy can result in a unique trajectory of potential symptoms and the potential for complete resolution of disease.
Children's Hospital of Philadelphia.
Laura
L
Smith
Children's Hospital of Philadelphia.
Kimberly
K
Venella
D000328:Adult; D064987:Cell- and Tissue-Based Therapy / Q000009:adverse effects*; D002678:Chimera / Q000276:immunology*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology*; D004509:Education, Nursing, Continuing; D006801:Humans; D007167:Immunotherapy; D007297:Inpatients; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects; D016896:Treatment Outcome; D055815:Young Adult
D011948:Receptors, Antigen, T-Cell
CAR T-cell therapy; cytokine release syndrome; immunotherapy ; pediatric patients